Bide Pharmatech (SH:688073) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-06 00:05Core Viewpoint - The major shareholders of Shanghai Bid Pharmaceutical Technology Co., Ltd. plan to reduce their holdings due to liquidity needs, with specific details on the number of shares and methods of reduction outlined in the announcement [1][2]. Shareholding Structure - As of the announcement date, major shareholder Zhoushan Xinxie Enterprise Management Partnership holds 5,019,806 shares, accounting for 5.52% of the total shares. Ningbo Landan Enterprise Management Partnership holds 4,305,076 shares, representing 4.74%, with 69,486 shares being subject to restrictions. Shareholder Wu Bo holds 785,804 shares, making up 0.86% of the total shares. Together, these shareholders hold a total of 11.12% of the company [1][2]. Reduction Plan Details - Zhoushan Xinxie plans to reduce up to 908,829 shares (1.00% of total shares) through block trading, while Ningbo Landan also plans to reduce up to 908,829 shares (1.00%). Wu Bo intends to reduce up to 785,804 shares (0.86%) through centralized bidding. The reduction prices will be determined based on market conditions at the time of the sale [2][3]. Shareholder Commitments - The major shareholders have made commitments regarding their shareholding, including a lock-up period of 12 months post-IPO during which they will not transfer or manage their shares. After this period, any reduction within 24 months will be based on market prices and not below the issue price [5][6][8]. Compliance with Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange rules. The shareholders are committed to adhering to these regulations and will disclose their reduction plans three trading days in advance [7][9][13].